BOOK
Pharmacology And Applications Of Chinese Materia Medica (Volume I)
But Paul Pui-hay | Chang Hson-mou | Wang Lai-ling
(1986)
Additional Information
Book Details
Abstract
This book is the first volume of a comprehensive 2-volume book covering modern pharmacological and clinical studies of the most commonly used Chinese herbal drugs. It contains monographs of 250 kinds of the most commonly used Chinese Materia Medica. The information on each herb was compiled by a research specialist active in the scientific investigation of that particular type of herb. The description on each drug includes an introduction (source, character and taste, actions and indications according to traditional Chinese medicine etc.), chemical composition, pharmacology, clinical studies, adverse effects and references. The translation of the book into English was done by qualified professionals in the field and the terms used are consistent with those used in Index Medicus, Chemical Abstracts and Botanical journals.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Title | iii | ||
| Copyright | iv | ||
| PREFACE TO THE ENGLISH EDITION | vii | ||
| PREFACE TO THE CHINESE EDITION | ix | ||
| EXPLANATORY NOTES OF THE CHINESE EDITION | xi | ||
| CONTENTS | xiii | ||
| YIYEQIU | 1 | ||
| CHEMICAL COMPOSITION | 1 | ||
| PHARMACOLOGY | 1 | ||
| 1. Central Stimulant Action | 1 | ||
| 2. Miscellaneous Actions | 2 | ||
| 3. Pharmacokinetics | 2 | ||
| 4. Toxicity | 3 | ||
| CLINICAL STUDIES | 4 | ||
| 1. Sequelae of Poliomyelitis | 4 | ||
| 2. Facial Paralysis | 4 | ||
| 3. Menopausal Syndrome | 4 | ||
| ADVERSE EFFECTS | 4 | ||
| REFERENCE | 4 | ||
| QIYELIAN | 6 | ||
| CHEMICAL COMPOSITION | 6 | ||
| PHARMACOLOGY | 6 | ||
| 1. Analgesic Effect | 6 | ||
| 2. Sedative and Hypnotic Effects | 7 | ||
| 3. Anticonvulsant Effect | 7 | ||
| 4. Effect on Smooth Muscles | 7 | ||
| 5. Effects on the Cardiovascular System | 8 | ||
| 6. Toxicity | 8 | ||
| CLINICAL STUDIES | 8 | ||
| 1. Analgesia | 8 | ||
| 2. Anti-asthma | 9 | ||
| ADVERSE EFFECTS | 9 | ||
| REFERENCE | 9 | ||
| BAJIAOFENG | 11 | ||
| CHEMICAL COMPOSITION | 11 | ||
| PHARMACOLOGY | 11 | ||
| 1. Muscle Relaxant Effect | 11 | ||
| 2. Effect on the Central Nervous System | 12 | ||
| 3. Effect on Respiration | 12 | ||
| 4. Effect on the Cardiovascular System | 12 | ||
| 5. Effect on Smooth Muscles | 13 | ||
| 6. Miscellaneous Actions | 13 | ||
| 7. Toxicity | 13 | ||
| CLINCAL STUDIES | 13 | ||
| 1. Compound Anesthesia | 13 | ||
| 2. Chronic Rheumatoid Arthritis | 14 | ||
| ADVERSE EFFECTS | 14 | ||
| REFERENCE | 14 | ||
| RENSHEN | 16 | ||
| CHEMICAL COMPOSITION | 16 | ||
| PHARMACOLOGY | 17 | ||
| 1. Effects on the Central Nervous System | 17 | ||
| 2. Influence on the Efferent Nervous System | 18 | ||
| 3. Effects on the Circulatory System | 18 | ||
| 4. Effect on Blood and Hematopoietic System | 20 | ||
| 5. Effects on the Endocrine System | 20 | ||
| 6. Influence on Metabolism | 21 | ||
| 7. Antifatigue Effect | 22 | ||
| 8. Increase of the Adaptability of the Organism | 23 | ||
| 9. Miscellaneous Actions | 23 | ||
| 10. Toxicity | 24 | ||
| CLINICAL STUDIES | 24 | ||
| 1. Emergency Treatment of Critical Patients | 24 | ||
| 2. Psychiatric and Neurologic Diseases | 24 | ||
| 3. Diseases of the Cardiovascular and Hematological Systems | 25 | ||
| 4. Diabetes Mellitus | 25 | ||
| 5. Diseases of the Digestive System | 25 | ||
| 6. As Tonics | 26 | ||
| 7. Neoplasms | 26 | ||
| 8. Miscellaneous | 26 | ||
| ADVERSE EFFECTS | 26 | ||
| REFERENCE | 27 | ||
| JIUJIEFENG | 30 | ||
| CHEMICAL COMPOSITION | 30 | ||
| PHARMACOLOGY | 30 | ||
| 1. Antineoplastic Action | 30 | ||
| 2. Effect on the Immunologic Function | 31 | ||
| 3. Antibacterial Action | 32 | ||
| 4. Effect on Experimental Gastric Ulcer | 32 | ||
| 5. Promotion of Bone Healing in Fractures | 33 | ||
| 6. Expectorant and Antiasthmatic Effects | 33 | ||
| 7. Miscellaneous Actions | 33 | ||
| 8. Toxicity | 33 | ||
| CLINICAL STUDIES | 34 | ||
| 1. Carcinomas | 34 | ||
| 2. Infectious Diseases | 34 | ||
| 3. Peptic Ulcer | 34 | ||
| 4. Fractures | 35 | ||
| 5. Rheumatoid Arthritis | 35 | ||
| 6. Psoriasis | 35 | ||
| 7. Miscellaneous | 35 | ||
| ADVERSE EFFECTS | 35 | ||
| REFERENCE | 36 | ||
| SANQI | 39 | ||
| CHEMICAL COMPOSITION | 39 | ||
| PHARMACOLOGY | 40 | ||
| 1. Actions on the Cardiovascular System | 40 | ||
| 2. Effect on Blood | 42 | ||
| 3. Anti-Inflammatory Effect | 43 | ||
| 4. Miscellaneous Actions | 43 | ||
| 5. Toxicity | 43 | ||
| CLINICAL STUDIES | 44 | ||
| 1. Coronary Disease | 44 | ||
| 2. Hemoptysis | 45 | ||
| 3. Hematuria | 45 | ||
| 4. Intraocular Hemorrhage | 45 | ||
| 5. Hyperlipidemia | 45 | ||
| 6. Reduction of GPT and Improvement of Abnormal Plasma Protein | 46 | ||
| 7. Head Injury | 46 | ||
| 8. Infantile Acute Nephritis | 46 | ||
| ADVERSE EFFECTS | 46 | ||
| REFERENCE | 47 | ||
| SANJIANSHAN | 50 | ||
| CHEMICAL COMPOSITION | 50 | ||
| PHARMACOLOGY | 50 | ||
| 1. Antineoplastic Action | 50 | ||
| 2. Effect on the Immunologic Function | 52 | ||
| 3. Action on the Coronary Blood Vessels | 52 | ||
| 4. Pharmacokinetics | 52 | ||
| 5. Toxicity | 52 | ||
| CLINICAL STUDIES | 53 | ||
| ADVERSE EFFECTS | 54 | ||
| REFERENCE | 54 | ||
| SANKEZHEN | 57 | ||
| CHEMICAL COMPOSITION | 57 | ||
| PHARMACOLOGY | 57 | ||
| CLINICAL STUDIES | 63 | ||
| 1. Acute Infections Diseases | 63 | ||
| 2. Leukopenia | 63 | ||
| 3. Hypertension | 63 | ||
| 4. Chronic Bronchitis and Others | 63 | ||
| ADVERSE EFFECTS | 64 | ||
| REFERENCE | 64 | ||
| DAHUANG | 67 | ||
| CHEMICAL COMPOSITION | 67 | ||
| PHARMACOLOGY | 67 | ||
| 1. Actions on the Digestive System | 67 | ||
| 2. Effect on Pathogenic Microorganisms | 70 | ||
| 3. Antineoplastic Action | 71 | ||
| 4. Effect on the Cardiovascular System | 72 | ||
| 5. Astringent and Hemostatic Actions | 72 | ||
| 6. Miscellaneous Actions | 72 | ||
| 7. Pharmacokinetics | 72 | ||
| 8. Toxicity | 73 | ||
| CLINICAL STUDIES | 73 | ||
| 1. Indigestion and Constipation | 73 | ||
| 2. Acute Inflammatory Diseases | 74 | ||
| 3. Infectious and Parasitic Diseases | 74 | ||
| 4. Hemorrhage and Thrombocytopenia | 74 | ||
| 5. Burns | 74 | ||
| 6. Skin Diseases | 75 | ||
| 7. Miscellaneous Actions | 75 | ||
| ADVERSE EFFECTS | 75 | ||
| REFERENCE | 75 | ||
| DASUAN | 79 | ||
| CHEMICAL COMPOSITION | 79 | ||
| PHARMACOLOGY | 79 | ||
| 1. Antibacterial Action | 79 | ||
| 2. Antiprotozoal and Antitrichomonal Actions | 80 | ||
| 3. Antineoplastic Action | 80 | ||
| 4. Effect on Blood Lipids | 81 | ||
| 5. Actions on the Cardiovascular System | 81 | ||
| 6. Effect on the Immunologic Function | 82 | ||
| 7. Miscellaneous Actions | 82 | ||
| 8. Pharmacokinetics | 82 | ||
| 9. Toxicity | 83 | ||
| CLINICAL STUDIES | 83 | ||
| 1. Bacillary Dysentery | 83 | ||
| 2. Amebic Dysentery | 83 | ||
| 3. Deep Fungal Infections | 83 | ||
| 4. Whooping Cough | 84 | ||
| 5. Endobronchial Tuberculosis | 84 | ||
| 6. Acute Appendicitis | 84 | ||
| 7. Oxyuriasis | 84 | ||
| 8. Trichomonas Vaginitis | 84 | ||
| 9. Hyperlipidemia | 84 | ||
| 10. Advanced Carcinoma | 85 | ||
| 11. Prevention and Treatment of Lead Poisoning | 85 | ||
| ADVERSE EFFECT | 85 | ||
| REFERENCE | 85 | ||
| DAQINGYE | 88 | ||
| CHEMICAL COMPOSITION | 88 | ||
| PHARMACOLOGY | 88 | ||
| 1. Action Against Pathogenic Microorganisms | 88 | ||
| 2. Antipyretic Action | 89 | ||
| 3. Anti-inflammatory Action | 89 | ||
| 4. Influence on Body Resistance | 89 | ||
| 5. Action on the Cardiovascular System | 89 | ||
| 6. Action on Smooth Muscles | 89 | ||
| 7. Pharmacokinetics | 90 | ||
| 8. Toxicity | 90 | ||
| CLINICAL STUDIES | 90 | ||
| 1. Upper Respiratory Tract Infection | 90 | ||
| 2. Encephalitis B | 90 | ||
| 3. Mumps | 91 | ||
| 4. Measles | 91 | ||
| 5. Infections Hepatitis | 91 | ||
| 6. Herpes simplex Keratitis | 91 | ||
| 7. Acute Infectious Lymphocytosis | 91 | ||
| 8. Miscellaneous | 91 | ||
| ADVERSE EFFECTS | 92 | ||
| REFERENCE | 92 | ||
| SHANZHA | 93 | ||
| CHEMICAL COMPOSITION | 93 | ||
| PHARMACOLOGY | 93 | ||
| 1. Action on the Cardiovascular System | 93 | ||
| 2. Antilipemic Action | 94 | ||
| 3. Antibacterial Action | 95 | ||
| 4. Action on the Central Nervous System | 95 | ||
| 5. Miscellaneous Actions | 95 | ||
| 6. Toxicity | 95 | ||
| CLINICAL STUDIES | 96 | ||
| 1. Hyperlipidemia | 96 | ||
| 2. Coronary and Other Heart Diseases | 96 | ||
| 3. Hypertension | 97 | ||
| 4. Dyspepsia | 97 | ||
| 5. Bacillary Dysentery and Enteritis | 97 | ||
| 6. Hepatitis | 97 | ||
| 7. Pyelonephritis | 97 | ||
| 8. Miscellaneous | 98 | ||
| REFERENCE | 98 | ||
| SHANDOUGEN | 100 | ||
| CHEMICAL COMPOSITION | 100 | ||
| PHARMACOLOGY | 100 | ||
| 1. Antineoplastic Action | 100 | ||
| 2. Incremental Effect on White Blood Cells | 101 | ||
| 3. Antiarrhythmia Action | 101 | ||
| 4. Antibacterial Action | 102 | ||
| 5. Antiasthmatic Action | 102 | ||
| 6. Miscellaneous Actions | 103 | ||
| 7. Pharmacokinetics | 103 | ||
| 8. Toxicity | 103 | ||
| CLINICAL STUDIES | 104 | ||
| 1. Carcinoma | 104 | ||
| 2. Leukopenia | 104 | ||
| 3. Anti-arrhythmia | 104 | ||
| 4. Bronchial Asthma and Chronic Asthmatic Bronchitis | 105 | ||
| 5. Cervix Erosion | 105 | ||
| 6. Bacillary Dysentery and Enteritis | 106 | ||
| 7. Miscellaneous | 106 | ||
| REFERENCE | 106 | ||
| SHANCIGU | 109 | ||
| CHEMICAL COMPOSITION | 109 | ||
| PHARMACOLOGY | 109 | ||
| 1. Antineoplastic Action | 109 | ||
| 2. Effect on Tissue Metabolism | 110 | ||
| 3. Stress Reaction | 110 | ||
| 4. Effect on White Blood Cells | 110 | ||
| 5. Miscellaneous Actions | 110 | ||
| 6. Pharmacokinetics | 111 | ||
| 7. Toxicity | 111 | ||
| CLINICAL STUDIES | 112 | ||
| 1. Chemotherapy of Neoplasm | 112 | ||
| 2. Chronic Persistent and Chronic Active Hepatitis | 112 | ||
| 3. Acute Gout | 113 | ||
| ADVERSE EFFECTS | 113 | ||
| REFERENCE | 113 | ||
| QIANLIGUANG | 115 | ||
| CHEMICAL COMPOSITION | 115 | ||
| PHARMACOLOGY | 115 | ||
| 1. Antibacterial Action | 115 | ||
| 2. Antileptospiral Action | 116 | ||
| 3. Antitrichomonal Action | 116 | ||
| 4. Miscellaneous Actions | 116 | ||
| 5. Toxicity | 116 | ||
| CLINICAL STUDIES | 117 | ||
| Acute Infectious Diseases | 117 | ||
| 2. Leptospirosis | 117 | ||
| 3. Trichomonas Vaginitis and Cervicitis | 117 | ||
| 4. Eye Diseases | 118 | ||
| 5. Surgical Infections | 118 | ||
| 6. Miscellaneous | 118 | ||
| ADVERSE EFFECTS | 118 | ||
| REFERENCE | 118 | ||
| CHUANXIONG | 121 | ||
| CHEMICAL COMPOSITION | 121 | ||
| PHARMACOLOGY | 121 | ||
| 1. Actions on the Heart | 121 | ||
| 2. Action on Coronary Circulation | 121 | ||
| 3. Actions on the Peripheral Blood Vessels and Blood Pressure | 122 | ||
| 4. Actions on Platelet Aggregation and Thrombosis | 123 | ||
| 5. Actions on Blood Lipids and Atherosclerotic Plaques | 123 | ||
| 6. Action on the Central Nervous System | 124 | ||
| 7. Action on Smooth Muscles | 124 | ||
| 8. Antiradiation Action | 124 | ||
| 9. Miscellaneous Actions | 125 | ||
| 10. Pharmacokinetics | 125 | ||
| 11. Toxicity | 125 | ||
| CLINICAL STUDIES | 126 | ||
| 1. Coronary Disease | 126 | ||
| 2. Obstructive Cerebrovascular Diseases | 126 | ||
| 3. Miscellaneous | 126 | ||
| ADVERSE EFFECTS | 127 | ||
| REFERENCE | 127 | ||
| CHUANBEIMU | 130 | ||
| CHEMICAL COMPOSITION | 130 | ||
| PHARMACOLOGY | 130 | ||
| 1. Antitussive and Expectorant Actions | 130 | ||
| 2. Action on the Circulatory System | 130 | ||
| 3. Miscellaneous Actions | 131 | ||
| 4. Toxicity | 131 | ||
| CLINICAL STUDIES | 131 | ||
| 1. Cough in Chronic or Acute Bronchitis and Upper Respiratory Tract Infection | 131 | ||
| 2. Cough in Plumonary Tuberculosis | 131 | ||
| 3. Painful Swelling of Pharynx | 131 | ||
| 4. Miscellaneous | 132 | ||
| REFERENCE | 132 | ||
| NUZHENZI (APPENDICES: NUZHENYE AND NUZHENPI) | 133 | ||
| CHEMICAL COMPOSITION | 133 | ||
| PHARMACOLOGY | 133 | ||
| 1. Incremental Effect on the White Blood Cells | 133 | ||
| 2. Effect on the Immunologic Function | 133 | ||
| 3. Actions on the Cardiovascular System | 133 | ||
| 4. Antineoplastic Action | 134 | ||
| 5. Miscellaneous Actions | 134 | ||
| 6. Toxicity | 134 | ||
| CLINICAL STUDIES | 134 | ||
| 1. Leukopenia | 134 | ||
| 2. Respiratory Tract Infection | 134 | ||
| 3. Hypertension | 134 | ||
| 4. Acute Icteric Hepatitis | 135 | ||
| 5. Central Retinitis and Early Cataract | 135 | ||
| 6. Miscellaneous | 135 | ||
| CHEMICAL COMPOSITION | 135 | ||
| PHARMACOLOGY | 135 | ||
| 1. Action on the Cardiovascular System | 135 | ||
| 2. Antitussive Action | 136 | ||
| 3. Action on Smooth Muscles | 136 | ||
| 4. Antibacterial and Antiviral Actions | 136 | ||
| 5. Toxicity | 136 | ||
| CLINICAL STUDIES | 136 | ||
| 1. Chronic Bronchitis | 136 | ||
| 2. Pneumonia | 136 | ||
| ADVERSE EFFECTS | 137 | ||
| REFERENCE | 137 | ||
| MAQIANZI | 139 | ||
| MADOULING | 145 | ||
| CHEMICAL COMPOSITION | 145 | ||
| PHARMACOLOGY | 139 | ||
| 1. Action on the Central Nervous System | 139 | ||
| 1.1 Action on the spinal cord. | 139 | ||
| 1.2 Action on the medulla oblongata. | 140 | ||
| 1.3 Action on the cerebral cortex. | 140 | ||
| 2. Action on the Digestive System | 140 | ||
| 3. Effect on the Respiratory System | 140 | ||
| 4. Antibacterial Action | 140 | ||
| 5. Miscellaneous Actions | 141 | ||
| 6. Pharmacokinetics | 141 | ||
| 7. Toxicity | 141 | ||
| CLINICAL STUDIES | 141 | ||
| 1. Neurological Diseases | 141 | ||
| 2. Chronic Bronchitis | 142 | ||
| 3. Chronic Aplastic Anemia | 142 | ||
| 4. Infectious Diseases | 142 | ||
| 5. Miscellaneous | 142 | ||
| ADVERSE EFFECTS | 143 | ||
| REFERENCE | 143 | ||
| PHARMACOLOGY | 145 | ||
| 1. Expectorant Action | 145 | ||
| 2. Action on Smooth Muscles | 145 | ||
| 3. Antibacterial Action | 145 | ||
| 4. Miscellaneous Actions | 146 | ||
| 5. Toxicity | 146 | ||
| CLINICAL STUDIES | 146 | ||
| 1. Chronic Bronchitis | 146 | ||
| 2. Infectious Disease | 146 | ||
| ADVERSE EFFECTS | 146 | ||
| REFERENCE | 147 | ||
| MASANG AND MASANGJISHENG | 148 | ||
| CHEMICAL COMPOSITION | 148 | ||
| PHARMACOLOGY | 148 | ||
| 1. Central Stimulant Action | 148 | ||
| 2. Actions on the Cardiovascular System | 149 | ||
| 3. Miscellaneous Actions | 150 | ||
| 4. Toxicity | 150 | ||
| CLINICAL STUDIES | 151 | ||
| 1. Schizophrenia | 151 | ||
| 2. Rheumatism and Numbness | 152 | ||
| 3. Second-Degree Burns | 152 | ||
| ADVERSE EFFECTS | 152 | ||
| REFERENCE | 153 | ||
| TIANHUAFEN | 155 | ||
| CHEMICAL COMPOSITION | 155 | ||
| PHARMACOLOGY | 155 | ||
| 1. Abortifacient and Anti-early Pregnancy Actions | 155 | ||
| 2. Antineoplastic Action | 156 | ||
| 3. Action on Blood Glucose | 156 | ||
| 4. Antibacterial Action | 157 | ||
| 5. Pharmacokinetics | 157 | ||
| 6. Toxicity | 158 | ||
| CLINICAL STUDIES | 159 | ||
| 1. Induced Abortion in Second Trimester | 159 | ||
| 2. Anti-early Pregnancy | 159 | ||
| 3. Delayed Abortion and Fetal Death | 159 | ||
| 4. Ectopic Pregnancy | 160 | ||
| 5. Hydatidiform Mole | 160 | ||
| 6. Malignant Hydatidiform Mole and Chorioepithelioma | 160 | ||
| 7. Diabetes Mellitus | 160 | ||
| 8. Dry Cough Due to Pathogenic \"Heat\" in the Lungs, Thirst and Dryness of Throat | 161 | ||
| 9. Mastitis and Others | 161 | ||
| ADVERSE EFFECTS | 161 | ||
| REFERENCE | 162 | ||
| TIANNANXING | 167 | ||
| CHEMICAL COMPOSITION | 167 | ||
| PHARMACOLOGY | 167 | ||
| 1. Anticonvulsant Action | 167 | ||
| 2. Sedative and Analgesic Actions | 167 | ||
| 3. Expectorant Action | 168 | ||
| 4. Anti-arrhythmia Action | 168 | ||
| 5. Antineoplastic Action | 168 | ||
| 6. Toxicity | 168 | ||
| CLINICAL STUDIES | 168 | ||
| 1. Stroke, Epilepsy, and Tetanus | 168 | ||
| 2. Carcinoma of the Cervix | 168 | ||
| 3. Facial Paralysis | 169 | ||
| 4. Neurodermatitis | 169 | ||
| ADVERSE EFFECTS | 169 | ||
| REFERENCE | 169 | ||
| TIANMA AND MIHUANJUN | 171 | ||
| CHEMICAL COMPOSITION | 171 | ||
| PHARMACOLOGY | 171 | ||
| 1. Sedative Action | 171 | ||
| 2. Anticonvulsant Action | 172 | ||
| 3. Hemodynamic Action | 172 | ||
| 4. Toxicity | 173 | ||
| CLINICAL STUDIES | 173 | ||
| 1. Essential or Renal Hypertension and Neurasthenia | 173 | ||
| 2. Pain | 174 | ||
| ADVERSE EFFECTS | 174 | ||
| REFERENCE | 174 | ||
| YUNMUXIANG | 176 | ||
| CHEMICAL COMPOSITION | 176 | ||
| PHARMACOLOGY | 176 | ||
| 1. Action on the Respiratory System | 176 | ||
| 2. Action on the Intestinal Tract | 177 | ||
| 3. Actions on the Heart and Blood Vessels | 177 | ||
| 4. Antibacterial Action | 178 | ||
| 5. Toxicity | 178 | ||
| CLINICAL STUDIES | 179 | ||
| 1. Dysentery | 179 | ||
| 2. Peptic Ulcer | 179 | ||
| 3. Bronchial Asthma | 179 | ||
| ADVERSE EFFECTS | 179 | ||
| REFERENCE | 179 | ||
| MUTONG | 181 | ||
| CHEMICAL COMPOSITION | 181 | ||
| PHARMACOLOGY | 181 | ||
| 1. Diuretic Action | 181 | ||
| 2. Action on the Heart and Blood Vessels | 182 | ||
| 3. Action on Smooth Muscles | 182 | ||
| 4. Antibacterial Action | 182 | ||
| 5. Miscellaneous Actions | 183 | ||
| 6. Toxicity | 183 | ||
| CLINICAL STUDIES | 183 | ||
| 1. Liver Cirrhosis and Cardiac or Renal Edema | 183 | ||
| 2. Miscellaneous | 183 | ||
| ADVERSE EFFECTS | 183 | ||
| REFERENCE | 184 | ||
| WUWEIZI | 185 | ||
| CHEMICAL COMPOSITION | 185 | ||
| PHARMACOLOGY | 185 | ||
| 1. Central Action | 185 | ||
| 2. Action on the Respiratory System | 186 | ||
| 3. Protection Against Hepatic Damage | 187 | ||
| 4. Excitatory Action on the Uterus | 188 | ||
| 5. Action on the Cardiovascular System | 188 | ||
| 6. Effect on Metabolism | 188 | ||
| 7. Adaptogen-Like Action | 189 | ||
| 8. Antibacterial Action | 189 | ||
| 9. Miscellaneous Actions | 189 | ||
| 10. Toxicity | 189 | ||
| CLINICAL STUDIES | 190 | ||
| 1. Acute, Chronic Persistent and Chronic Hepatitis, and Drug-Induced Liver Damage | 190 | ||
| 2. Neurosis | 190 | ||
| 3. Psychosis | 191 | ||
| 4. Stroke and Other Neurologic Diseases | 191 | ||
| 5. Induction of Labor | 191 | ||
| 6. Bacillary Dysentery and Other Acute Intestinal Infections | 191 | ||
| 7. Latent Keshan Disease | 191 | ||
| 8. Impairment of Vision | 191 | ||
| 9. Meniere' s Syndrome | 191 | ||
| ADVERSE EFFECTS | 192 | ||
| REFERENCE | 192 | ||
| CHEQIANCAO AND CHEQIANZI | 195 | ||
| CHEMICAL COMPOSITION | 195 | ||
| PHARMACOLOGY | 195 | ||
| 1. Diuretic Action | 195 | ||
| 2. Expectorant and Antitussive Actions | 195 | ||
| 3. Antimicrobial Action | 196 | ||
| 4. Action on the Gastrointestinal Tract | 196 | ||
| 5. Actions on the Cardiovascular System | 196 | ||
| 6. Miscellaneous Actions | 196 | ||
| 7. Toxicity | 196 | ||
| CLINICAL STUDIES | 197 | ||
| 1. Respiratory Tract Infections | 197 | ||
| 2. Acute Icteric Hepatitis | 197 | ||
| 3. Intestinal Infections | 197 | ||
| 4. Urinary Tract Diseases | 197 | ||
| 5. Miscellaneous | 198 | ||
| REFERENCE | 198 | ||
| NIUHUANG | 199 | ||
| CHEMICAL COMPOSITION | 199 | ||
| PHARMACOLOGY | 199 | ||
| 1. Actions on the Central System | 199 | ||
| 2. Antimicrobial Action | 200 | ||
| 3. Anti-inflammatory, Antiallergic and Detoxicant Actions | 200 | ||
| 4. Actions on the Respiratory System | 201 | ||
| 5. Actions on the Circulatory System | 201 | ||
| 6. Actions on the Blood and Hematopoietic System | 201 | ||
| 7. Actions on the Digestive System | 201 | ||
| 8. Miscellaneous Actions | 202 | ||
| 9. Toxicity | 202 | ||
| CLINICAL STUDIES | 203 | ||
| 1. Acute Infectious Disease | 203 | ||
| 2. Inflammatory Diseases of the Eye, Ear, Nose and Mouth | 203 | ||
| 3. Surgical Infections | 204 | ||
| 4. Miscellaneous | 204 | ||
| ADVERSE EFFECTS | 204 | ||
| REFERENCE | 205 | ||
| NIUXI | 207 | ||
| CHEMICAL COMPOSITION | 207 | ||
| PHARMACOLOGY | 207 | ||
| 1. Action on Protein Anabolism | 207 | ||
| 2. Actions on the Cardiovascular System | 208 | ||
| 3. Actions on the Uterus | 208 | ||
| 4. Actions on the Intestinal Tract | 209 | ||
| 5. Anti-inflammatory and Analgesic Actions | 209 | ||
| 6. Diuretic Action | 209 | ||
| 7. Miscellaneous Actions | 209 | ||
| 8. Toxicity | 209 | ||
| 9. Pharmacokinetics | 209 | ||
| CLINICAL STUDIES | 210 | ||
| 1. Induction of Labor | 210 | ||
| 2. Diphtheria | 210 | ||
| 3. Pneumonia in Children | 210 | ||
| 4. Urinary Lithiasis | 210 | ||
| REFERENCE | 210 | ||
| MAODONGQING | 212 | ||
| CHEMICAL COMPOSITION | 212 | ||
| PHARMACOLOGY | 212 | ||
| 1. Actions on the Cardiovascular System | 212 | ||
| 2. Effect on Lipid Metabolism | 213 | ||
| 3. Antibacterial Action | 213 | ||
| 4. Miscellaneous Actions | 213 | ||
| 5. Toxicity | 213 | ||
| CLINICAL STUDIES | 214 | ||
| 1. Coronary Disease | 214 | ||
| 2. Cerebral Thrombosis | 214 | ||
| 3. Thromboangiitis Obliterans | 214 | ||
| 4. Central Retinitis | 214 | ||
| 5. Burns | 215 | ||
| 6. Miscellaneous | 215 | ||
| ADVERSE EFFECTS | 215 | ||
| REFERENCE | 215 | ||
| SHENGMA | 218 | ||
| CHEMICAL COMPOSITION | 218 | ||
| PHARMACOLOGY | 218 | ||
| 1. Antipyretic and Hypothermic Actions | 218 | ||
| 2. Anti-inflammatory Action | 218 | ||
| 3. Analgesic Action | 219 | ||
| 4. Anticonvulsant Action | 219 | ||
| 5. Action on Smooth Muscles | 219 | ||
| 6. Actions on the Cardiovascular System | 219 | ||
| 7. Antibacterial Action | 219 | ||
| 8. Miscellaneous Actions | 220 | ||
| 9. Toxicity | 220 | ||
| CLINICAL STUDIES | 220 | ||
| 1. Infectious Diseases | 220 | ||
| 2. Uterine Prolapse | 220 | ||
| 3. Mouth Diseases | 220 | ||
| 4. Miscellaneous | 221 | ||
| ADVERSE EFFECTS | 221 | ||
| REFERENCE | 221 | ||
| CHANGCHUNHUA | 223 | ||
| CHEMICAL COMPOSITION | 223 | ||
| PHARMACOLOGY | 223 | ||
| 1. Antineoplastic Action | 223 | ||
| 2. Hypotensive and Vasodilatory Actions | 224 | ||
| 3. Hypoglycemic Action | 225 | ||
| 4. Diuretic action | 225 | ||
| 5. Pharmacokinetics | 225 | ||
| 6. Toxicity | 225 | ||
| CLINICAL STUDIES | 226 | ||
| 1. Carcinomas | 226 | ||
| 2. Hypertension | 226 | ||
| ADVERSE EFFECTS | 226 | ||
| REFERENCE | 227 | ||
| WUYAO | 228 | ||
| CHEMICAL COMPOSITION | 228 | ||
| PHARMACOLOGY | 228 | ||
| 1. Effect on the Digestive Tract | 228 | ||
| 2. Hemostatic Action | 228 | ||
| 3. Antibacterial Action | 229 | ||
| 4. Miscellaneous Action | 229 | ||
| CLINICAL STUDIES | 229 | ||
| 1. Diseases of the Digestive System | 229 | ||
| 2. Diseases of the Urinary System | 229 | ||
| 3. Rheumatic Lumbago | 229 | ||
| REFERENCE | 230 | ||
| WUMEI | 231 | ||
| CHEMICAL COMPOSITION | 231 | ||
| PHARMACOLOGY | 231 | ||
| 1. Inhibitory Action on Ascarides | 231 | ||
| 2. Antimicrobial Action | 231 | ||
| 3. Action on Smooth Muscles | 231 | ||
| 4. Antiallergic Action | 232 | ||
| 5. Miscellaneous Actions | 232 | ||
| CLINICAL STUDIES | 232 | ||
| 1. Biliary Ascariasis | 232 | ||
| 2. Intestinal Obstruction Due to Ascarides | 232 | ||
| 3. Ancylostomiasis | 233 | ||
| 4. Intestinal Infections | 233 | ||
| 5. Leukorrhea and Lochia | 233 | ||
| 6. Psoriasis | 233 | ||
| 7. Callus and Corns | 233 | ||
| 8. Treatment of Various Polyps | 234 | ||
| 9. Miscellaneous | 234 | ||
| REFERENCE | 234 | ||
| DANSHEN | 237 | ||
| CHEMICAL COMPOSITION | 237 | ||
| PHARMACOLOGY | 237 | ||
| 1. Actions on Coronary Circulation | 237 | ||
| 2. Actions on Myocardial Ischemia and Infarction | 238 | ||
| 3. Actions on Blood Pressure and Peripheral Blood Vessels | 238 | ||
| 4. Actions on the Heart | 239 | ||
| 5. Actions on Microcirculation and Hemorheology | 239 | ||
| 6. Actions on Blood Coagulation, Fibrinolysis, Platelet Aggregation and Thrombosis | 239 | ||
| 7. Effect on Hypoxia Tolerance | 240 | ||
| 8. Effects on Blood Lipids and Formation of Atheromatous Plaques | 240 | ||
| 9. Actions on the Central Nervous System | 241 | ||
| 10. Bacteriostatic Action | 241 | ||
| 11. Effects on the Immunologic Function | 241 | ||
| 12. Action on Metabolism of DNA | 241 | ||
| 13. Miscellaneous Actions | 242 | ||
| 14. Pharmacokinetics of Tanshinone IIA Sodium Sulfonate | 242 | ||
| 15. Toxicity | 243 | ||
| CLINICAL STUDIES | 243 | ||
| 1. Coronary Disease and Hypertension | 243 | ||
| 2. Cerebrovascular Disease | 243 | ||
| 3. Diffused Intravascular Coagulation (DIC) | 244 | ||
| 4. Angiitis | 244 | ||
| 5. Hepatitis | 244 | ||
| 6. Suppurative and Surgical Infections | 244 | ||
| 7. Skin Diseases | 245 | ||
| 8. Miscellaneous | 245 | ||
| ADVERSE EFFECTS | 245 | ||
| REFERENCE | 245 | ||
| BADOU | 250 | ||
| CHEMICAL COMPOSITION | 250 | ||
| PHARMACOLOGY | 250 | ||
| 1. Actions on the Digestive Tract | 250 | ||
| 2. Antimicrobial Action | 251 | ||
| 3. Antineoplastic Action | 251 | ||
| 4. Carcinogenic Action | 251 | ||
| 5. Effect on Protein Synthesis | 252 | ||
| 6. Analgesic Action | 252 | ||
| 7. Actions on the Circulatory and Respiratory Systems | 252 | ||
| 8. Actions on Blood | 252 | ||
| 9. Miscellaneous Actions | 252 | ||
| 10. Toxicity | 253 | ||
| CLINICAL STUDIES | 253 | ||
| 1. Intestinal Obstruction | 253 | ||
| 2. Biliary Colic and Biliary Tract Ascariasis | 253 | ||
| 3. Appendicitis and Chronic Diarrhea | 253 | ||
| 4. Malaria | 253 | ||
| 5. Acute Mastitis | 254 | ||
| 6. Miscellaneous | 254 | ||
| ADVERSE EFFECTS | 254 | ||
| REFERENCE | 254 | ||
| SHUINIUJIAO | 257 | ||
| CHEMICAL COMPOSITION | 257 | ||
| PHARMACOLOGY | 257 | ||
| 1. Action on the Blood | 257 | ||
| 2. Actions on the Pituitary-Adrenocortical System | 257 | ||
| 3. Sedative and Anticonvulsant Actions | 258 | ||
| 4. Gonadotrophin-Like Action | 258 | ||
| 5. Miscellaneous Actions | 258 | ||
| CLINICAL STUDIES | 258 | ||
| 1. Schizophrenia | 258 | ||
| 2. Encephalitis B | 258 | ||
| 3. Idiopathic Thrombopenic Purpure Hemorrhagica | 259 | ||
| 4. Rheumatic and Rheumatoid Arthritis | 259 | ||
| 5. Miscellaneous | 259 | ||
| ADVERSE EFFECTS | 259 | ||
| REFERENCE | 260 | ||
| SHUICHANGPU | 261 | ||
| CHEMICAL COMPOSITION | 261 | ||
| PHARMACOLOGY | 261 | ||
| 1. Anti-arrhythmia Action | 261 | ||
| 2. Inhibitory Action on the Heart | 262 | ||
| 3. Hypotensive Action | 262 | ||
| 4. Actions on the Central Nervous System | 262 | ||
| 5. Antitussive, Expectorant and Antiasthmatic Actions | 263 | ||
| 6. Antibacterial Action | 264 | ||
| 7. Miscellaneous Actions | 264 | ||
| 8. Toxicity | 264 | ||
| CLINICAL STUDIES | 265 | ||
| 1.Chronic Bronchitis | 265 | ||
| ADVERSE EFFECTS | 265 | ||
| REFERENCE | 265 | ||
| YUZHU | 267 | ||
| CHEMICAL COMPOSITION | 267 | ||
| PHARMACOLOGY | 267 | ||
| 1. Actions on the Heart | 267 | ||
| 2. Actions on Blood Vessels | 267 | ||
| 3. Effect on Blood Pressure | 268 | ||
| 4. Effect on Blood Lipids and Experimental Atherosclerotic Plaques | 268 | ||
| 5. Action on Smooth Muscles | 268 | ||
| 6. Miscellaneous Actions | 268 | ||
| 7. Toxicity | 269 | ||
| CLINICAL STUDIES | 269 | ||
| 1. Heart Failure | 269 | ||
| 2. Hyperlipidemia | 269 | ||
| REFERENCE | 269 | ||
| YUMIXU | 271 | ||
| CHEMICAL COMPOSITION | 271 | ||
| PHARMACOLOGY | 271 | ||
| 1. Diuretic Action | 271 | ||
| 2. Hypotensive Action | 271 | ||
| 3. Choleretic Action | 272 | ||
| 4. Miscellaneous Actions | 272 | ||
| 5. Toxicity | 273 | ||
| CLINICAL STUDIES | 273 | ||
| 1. Edema of Various Etiologies | 273 | ||
| 2. Hepatobiliary Diseases | 273 | ||
| 3. Hypertension | 273 | ||
| 4. Chyluria and Hematuria | 273 | ||
| REFERENCE | 274 | ||
| Al | 275 | ||
| CHEMICAL COMPOSITION | 275 | ||
| PHARMACOLOGY | 275 | ||
| 1. Antiasthmatic Action | 275 | ||
| 2. Antitussive Action | 276 | ||
| 3. Expectorant Action | 276 | ||
| 4. Antiallergic Action | 276 | ||
| 5. Actions on the Cardiovascular System | 276 | ||
| 6. Central Actions | 276 | ||
| 7. Antibacterial Action | 277 | ||
| 8. Miscellaneous Actions | 277 | ||
| 9. Toxicity | 277 | ||
| CLINICAL STUDIES | 278 | ||
| 1. Chronic Bronchitis | 278 | ||
| 2. Allergic Diseases | 278 | ||
| 3. Disinfection of Rooms and Burns | 278 | ||
| 4. Miscellaneous | 278 | ||
| ADVERSE EFFECTS | 279 | ||
| REFERENCE | 279 | ||
| GANCAO | 281 | ||
| CHEMICAL COMPOSITION | 281 | ||
| PHARMACOLOGY | 281 | ||
| 1. Adrenocorticomimetic Action | 281 | ||
| 2. Anti-inflammatory Action | 282 | ||
| 3. Effect on the Immunologic Function | 283 | ||
| 4. Actions on the Digestive System | 283 | ||
| 5. Detoxicant Action | 285 | ||
| 6. Antitussive and Expectorant Actions | 285 | ||
| 7. Antilipemic Action | 286 | ||
| 8. Antineoplastic Action | 286 | ||
| 9. Miscellaneous Actions | 286 | ||
| 10. Toxicity | 288 | ||
| CLINICAL STUDIES | 289 | ||
| 1. Diseases of the Endocrine System | 289 | ||
| 2. Gastric and Doudenal Ulcer | 289 | ||
| 3. Pulmonary Tuberculosis | 290 | ||
| 4. Infectious Hepatitis | 290 | ||
| 5. Eyes Inflammatory Diseases | 290 | ||
| 6. Frostbite | 290 | ||
| 7. Spasm of Gastrocnemius Muscles | 290 | ||
| 8. Purpura | 290 | ||
| ADVERSE EFFECTS | 291 | ||
| REFERENCE | 291 | ||
| SHISUAN | 294 | ||
| CHEMICAL COMPOSITION | 294 | ||
| PHARMACOLOGY | 294 | ||
| 1. Anticholinesterase Action | 294 | ||
| 2. Action on the Neuromuscular Junction | 294 | ||
| 3. Action on the Central Nervous System | 295 | ||
| 4. Actions on the Cardiovascular System | 295 | ||
| 5. Anti-inflammatory Action | 296 | ||
| 6. Action on Smooth Muscles | 296 | ||
| 7. Emetic Action | 297 | ||
| 8. Antineoplastic Action | 297 | ||
| 9. Uricosuric Action | 297 | ||
| 10. Toxicity | 297 | ||
| CLINICAL STUDIES | 298 | ||
| 1. Hemiplegia | 298 | ||
| 2. Sequelae of Poliomyelitis | 298 | ||
| 3. Rheumatic Arthritis | 298 | ||
| 4. Carcinoma | 298 | ||
| 5. As Insecticide and Rodenticide | 299 | ||
| ADVERSE EFFECTS | 299 | ||
| REFERENCE | 299 | ||
| SHIGAO | 301 | ||
| CHEMICAL COMPOSITION | 301 | ||
| PHARMACOLOGY | 301 | ||
| 1. Effect on Fever | 301 | ||
| 2. Effect on the Immunologic Function | 302 | ||
| 3. Miscellaneous Actions | 302 | ||
| 4. Pharmacokinetics | 303 | ||
| CLINICAL STUDIES | 303 | ||
| 1. High Fever | 303 | ||
| 2. Burns | 303 | ||
| 3. Osteoarthrosis Deformans (Kaschin-Beck's Disease Prevalent in Northern China) | 303 | ||
| 4. Miscellaneous | 304 | ||
| REFERENCES | 304 | ||
| SHIDIAOLAN | 306 | ||
| CHEMICAL COMPOSITION | 306 | ||
| PHARMACOLOGY | 306 | ||
| 1. Antibacterial Action | 306 | ||
| 2. Anti-inflammatory Action | 306 | ||
| 3. Antitussive, Expectorant and Antiasthmatic Action | 307 | ||
| 4. Hypotensive Action | 307 | ||
| 5. Sedative Action | 308 | ||
| CLINICAL STUDIES | 308 | ||
| 1. Tuberculosis | 308 | ||
| 2. Chronic Bronchitis | 308 | ||
| ADVERSE EFFECTS | 308 | ||
| REFERENCE | 309 | ||
| SHICHANGPU | 310 | ||
| CHEMICAL COMPOSITION | 310 | ||
| PHARMACOLOGY | 310 | ||
| 1. Actions on the Central Nervous System | 310 | ||
| 2. Antispasmodic Action | 310 | ||
| 3. Miscellaneous Actions | 311 | ||
| 4. Toxicity | 311 | ||
| CLINICAL STUDIES | 311 | ||
| 1. Grand Mal Epilepsy | 311 | ||
| 2. Coma Due to Pulmonary Brain Diseases and Encephalitis | 311 | ||
| 3. Bronchial Asthma | 312 | ||
| ADVERSE EFFECTS | 312 | ||
| REFERENCE | 312 | ||
| LONGDAN | 314 | ||
| CHEMICAL COMPOSITION | 314 | ||
| PHARMACOLOGY | 314 | ||
| 1. Stomachic Effect | 314 | ||
| 2. Action on the Liver | 314 | ||
| 3. Choleretic Action | 314 | ||
| 4. Diuretic Action | 315 | ||
| 5. Hypotensive Action | 315 | ||
| 6. Actions on the Central Nervous System | 315 | ||
| 7. Anti-inflammatory Action | 315 | ||
| 8. Antibacterial Action | 316 | ||
| 9. Miscellaneous Actions | 316 | ||
| 10. Toxicity | 316 | ||
| CLINICAL STUDIES | 316 | ||
| 1. As Appetizer | 316 | ||
| 2. Hepatitis | 316 | ||
| 3. Encephalitis B | 317 | ||
| 4. Miscellaneous | 317 | ||
| ADVERSE EFFECTS | 317 | ||
| REFERENCE | 318 | ||
| LONGKUI | 319 | ||
| CHEMICAL COMPOSITION | 319 | ||
| PHARMACOLOGY | 319 | ||
| 1. Anti-inflammatory and Antishock Action | 319 | ||
| 2. Antiallergic Action | 319 | ||
| 3. Antipyretic and Analgesic Actions | 320 | ||
| 4. Expectorant, Antitussive and Antiasthmatic Actions | 320 | ||
| 5. Antibacterial Action | 320 | ||
| 6. Antineoplastic Action | 320 | ||
| 7. Antivenin Action | 321 | ||
| 8. Hyperglycemic Effect | 321 | ||
| 9. Incremental Effect on Leukocytes | 321 | ||
| 10. Cardiotonic Action | 321 | ||
| 11. Hypotensive Action | 322 | ||
| 12. Anticholinesterase Action | 322 | ||
| 13. Miscellaneous Actions | 322 | ||
| 14. Pharmacokinetics | 323 | ||
| 15. Toxicity | 323 | ||
| CLINICAL STUDIES | 324 | ||
| 1. Chronic Bronchitis | 324 | ||
| 2. Carcinoma | 324 | ||
| 3. Hypertension | 325 | ||
| 4. \"Asthenia of Blood\" and Vertigo | 325 | ||
| 5. Poisonous Snake Bites | 325 | ||
| 6. Eczema and Dermatitis | 325 | ||
| 7. Urticaria | 325 | ||
| 8. Cervix Erosion | 325 | ||
| 9. Leukorrhea | 326 | ||
| 10. Miscellaneous | 326 | ||
| ADVERSE EFFECTS | 326 | ||
| REFERENCE | 326 | ||
| SIJIQING | 329 | ||
| CHEMICAL COMPOSITION | 329 | ||
| PHARMACOLOGY | 329 | ||
| 1. Antibacterial Action | 329 | ||
| 2. Effect on Experimental Burns | 330 | ||
| 3. Actions on the Cardiovascular System | 330 | ||
| 4. Miscellaneous Actions | 332 | ||
| 5. Pharmacokinetics | 332 | ||
| 6. Toxicity | 333 | ||
| CLINICAL STUDIES | 334 | ||
| 1. Burns | 334 | ||
| 2. Infectious Diseases | 334 | ||
| 3. Leg and Leprous Ulcers | 334 | ||
| 4. Heart and Peripheral Vascular Diseases | 334 | ||
| 5. Miscellaneous | 335 | ||
| ADVERSE EFFECTS | 335 | ||
| REFERENCE | 336 | ||
| BEIDOUGEN | 338 | ||
| CHEMICAL COMPOSITION | 338 | ||
| PHARMACOLOGY | 338 | ||
| 1. Muscle Relaxant Action | 338 | ||
| 2. Bacteriostatic Action | 338 | ||
| 3. Antitussive and Expectorant Actions | 338 | ||
| 4. Miscellaneous Actions | 339 | ||
| 5. Toxicity | 339 | ||
| CLINICAL STUDIES | 339 | ||
| 1. Chronic Bronchitis | 339 | ||
| 2. As Adjuvant in Anesthesia | 340 | ||
| 3. Miscellaneous Actions | 340 | ||
| REFERENCE | 340 | ||
| SHENGJIANG | 341 | ||
| CHEMICAL COMPOSITION | 341 | ||
| PHARMACOLOGY | 341 | ||
| 1. Action on the Digestive System | 341 | ||
| 2. Antiemetic Action | 341 | ||
| 3. Anti-inflammatory Action | 342 | ||
| 4. Analgesic Action | 342 | ||
| 5. Miscellaneous Actions | 342 | ||
| 6. Toxicity | 342 | ||
| CLINICAL STUDIES | 342 | ||
| 1. Rheumatic Pain, Lumbago, and Pain of Lower Extremities | 342 | ||
| 2. Gastric and Duodenal Ulcers | 343 | ||
| 3. Acute Bacillary Dysentery | 343 | ||
| 4. Intestinal Obstruction Due to Ascariasis | 343 | ||
| 5. \"Warming of Abdominal Cavity\" and Antiemesis | 343 | ||
| REFERENCE | 343 | ||
| XIANHECAO | 345 | ||
| CHEMICAL COMPOSITION | 345 | ||
| PHARMACOLOGY | 345 | ||
| 1. Hemostatic Action | 345 | ||
| 2. Action on the Circulatory System | 345 | ||
| 3. Actions on Smooth Muscles | 346 | ||
| 4. Anti-inflammatory Action | 346 | ||
| 5. Action Against Trichomonas vaginalis | 346 | ||
| 6. Antibacterial Action | 346 | ||
| 7. Miscellaneous Actions | 346 | ||
| CLINICAL STUDIES | 347 | ||
| 1. Hematemesis, Hemoptysis, and Internal Bleeding | 347 | ||
| 2. Enteritis, Trichomonal Enteritis, and Bacillary Dysentery | 347 | ||
| 3. Vaginal Trichomoniasis | 347 | ||
| ADVERSE EFFECTS | 347 | ||
| REFERENCE | 347 | ||
| BAIZHU | 349 | ||
| CHEMICAL COMPOSITION | 349 | ||
| PHARMACOLOGY | 349 | ||
| 1. Tonic Action | 349 | ||
| 2. Diuretic Action | 349 | ||
| 3. Hypoglycemic Action | 350 | ||
| 4. Anticoagulant Action | 350 | ||
| 5. Actions on the Cardiovascular System | 350 | ||
| 6. Antineoplastic Action | 350 | ||
| 7. Miscellaneous Actions | 351 | ||
| 8. Toxicity | 351 | ||
| CLINICAL STUDIES | 351 | ||
| 1. Constipation After Gynecological Operation | 351 | ||
| 2. Dyspepsia | 352 | ||
| 3. Abnormal Fetal Movements | 352 | ||
| 4. Perspiration and Salivation | 352 | ||
| 5. Vertigo | 352 | ||
| 6. Leukopenia | 352 | ||
| 7. Edema of the Face and Extremities, and of Pregnancy | 352 | ||
| REFERENCE | 352 | ||
| BAITOUWENG | 354 | ||
| CHEMICAL COMPOSITION | 354 | ||
| PHARMACOLOGY | 354 | ||
| 1. Antibacterial Action | 354 | ||
| 2. Action Against the Amoebic Protozoa | 355 | ||
| 3. Inhibitory Action Against Other Pathogenic Organisms | 355 | ||
| 4. Miscellaneous Actions | 356 | ||
| 5. Toxicity | 356 | ||
| CLINICAL STUDIES | 356 | ||
| 1. Bacillary Dysentery | 356 | ||
| 2. Amoebic Dysentery | 356 | ||
| 3. Lymph Node Tuberculosis | 357 | ||
| 4. Carcinoma | 357 | ||
| 5. Miscellaneous | 357 | ||
| ADVERSE EFFECTS | 357 | ||
| REFERENCE | 358 | ||
| BAIMAOGEN (APPENDIX: BAIMAOHUA | 361 | ||
| CHEMICAL COMPOSITION | 361 | ||
| PHARMACOLOGY | 361 | ||
| 1. Diuretic Action | 361 | ||
| 2. Caogulant Action | 361 | ||
| 3. Effect on Myocardial 86Rb Uptake | 361 | ||
| 4. Miscellaneous Actions | 362 | ||
| 5. Toxicity | 362 | ||
| CLINICAL STUDIES | 362 | ||
| 1. Acute and Chronic Glomerulonephritis | 362 | ||
| 2. Epistaxis, Hemoptysis, hematuria, Menorrhagia, Upper Gastrointestinal Bleeding | 362 | ||
| 3. Acute Viral Hepatitis | 362 | ||
| ADVERSE EFFECTS | 362 | ||
| APPENDIX: |
363 | ||
| REFERENCE | 363 | ||
| BAIQUCAI | 364 | ||
| CHEMICAL COMPOSITION | 364 | ||
| PHARMACOLOGY | 364 | ||
| 1. Actions on the Nervous Systems | 364 | ||
| 2. Antineoplastic Action | 364 | ||
| 3. Action on Smooth Muscles | 365 | ||
| 4. Antibacterial Actions | 365 | ||
| 5. Expectorant and Antitussive Actions | 366 | ||
| 6. Actions on the Cardiovascular System | 366 | ||
| 7. Miscellaneous Actions | 366 | ||
| 8. Toxicity | 367 | ||
| CLINICAL STUDIES | 367 | ||
| 1. The dosage for gastritis, gastric ulcer, enteritis, abdominal pain, dysentery, and jaundice is 3-9 g. | 367 | ||
| 2. Bronchitis and Whooping Cough | 367 | ||
| 3. Paddy Field Dermatitis and Poisonous Insect Bites | 367 | ||
| ADVERSE EFFECTS | 367 | ||
| REFERENCE | 368 | ||
| BAIHUASHESHECAO | 369 | ||
| CHEMICAL COMPOSITION | 369 | ||
| PHARMACOLOGY | 369 | ||
| 1. Antibacterial Action | 369 | ||
| 2. Effect on the Phagocytic Function of the Reticuloendothelial System | 369 | ||
| 3. Effect on the Adrenocortical Function | 370 | ||
| 4. Antineoplastic Action | 370 | ||
| 5. Antisperntatogenic Action | 370 | ||
| 6. Influence on the Motility of the Gastrointestinal Tract | 371 | ||
| 7. Miscellaneous Actions | 371 | ||
| 8. Toxicity | 371 | ||
| CLINICAL STUDIES | 371 | ||
| 1. Acute Simple Appendicitis and Mild Local Peritonitis | 371 | ||
| 2. Pelvic Inflammatory Disease and Urinary Tract Infection | 372 | ||
| 3. Mumps and Chronic Bronchitis | 372 | ||
| 4. Hepatitis and Biliary Tract Infection | 372 | ||
| 5. Epididymic Stasis | 373 | ||
| 6. Carcinoma | 373 | ||
| 7. Miscellaneous | 373 | ||
| ADVERSE EFFECTS | 374 | ||
| REFERENCE | 374 | ||
| GUALOU | 377 | ||
| CHEMICAL COMPOSITION | 377 | ||
| PHARMACOLOGY | 377 | ||
| 1. Expectorant Action | 377 | ||
| 2. Cathartic Action | 377 | ||
| 3. Actions on the Cardiovascular System | 377 | ||
| 4. Antibacterial Action | 378 | ||
| 5. Miscellaneous Actions | 378 | ||
| 6. Toxicity | 378 | ||
| CLINICAL STUDIES | 379 | ||
| 1. Acute Bronchitis, Etc. | 379 | ||
| 2. Constipation | 379 | ||
| 3. Coronary Disease and Angina Pectoris | 379 | ||
| 4. Mastitis, Costal Chondritis, Etc | 380 | ||
| 5. Miscellaneous | 380 | ||
| ADVERSE EFFECTS | 380 | ||
| REFERENCE | 381 | ||
| DONGCHONGXIACAO | 383 | ||
| CHEMICAL COMPOSITION | 383 | ||
| PHARMACOLOGY | 383 | ||
| 1. Antiasthmatic Action | 383 | ||
| 2. Actions on the Heart and Blood Vessels | 383 | ||
| 3. Actions on the Smooth Muscles of Intestine and Uterus | 384 | ||
| 4. Antineoplastic Action | 384 | ||
| 5. Antibacterial Action | 384 | ||
| 6. Miscellaneous Actions | 384 | ||
| 7. Toxicity | 385 | ||
| CLINICAL STUDIES | 385 | ||
| 1. Lung Asthenia, Hemoptysis, \"kidney\" Asthenia and Impotence | 385 | ||
| 2. Terminal Carcinoma | 385 | ||
| REFERENCE | 385 | ||
| DONGLINGCAO | 387 | ||
| CHEMICAL COMPOSITION | 387 | ||
| PHARMACOLOGY | 387 | ||
| 1. Antineoplastic Action | 387 | ||
| 2. Effects on Immunologic Function | 389 | ||
| 3. Antibacterial Action | 389 | ||
| 4. Inhibition of the Hyperplastic Carcinomatous Change of the Esophageal Epithelium | 389 | ||
| 5. Miscellaneous Actions | 390 | ||
| 6. Toxicity | 390 | ||
| 7. Pharmacokinetics | 391 | ||
| CLINICAL STUDIES | 391 | ||
| 1. Carcinoma of the Esophagus | 391 | ||
| 2. Carcinoma of the Liver | 392 | ||
| 3. Other Carcinomas | 393 | ||
| 4. Epithelial Hyperplasia of the Esophagus | 393 | ||
| 5. Acute Suppurative Tonsillitis | 393 | ||
| ADVERSE EFFECTS | 393 | ||
| REFERENCE | 394 | ||
| XUANSHEN | 396 | ||
| CHEMICAL COMPOSITION | 396 | ||
| PHARMACOLOGY | 396 | ||
| 1. Actions on the Cardiovascular System | 396 | ||
| 2. Central Inhibitory Action | 396 | ||
| 3. Hypoglycemic Action | 397 | ||
| 4. Antipyretic Action | 397 | ||
| 5. Actions Against Pathogenic Microorganisms and Their Toxins | 397 | ||
| 6. Miscellaneous Actions | 397 | ||
| 7. Toxicity | 398 | ||
| CLINICAL STUDIES | 398 | ||
| REFERENCE | 398 | ||
| HANFANGJI | 400 | ||
| CHEMICAL COMPOSITION | 400 | ||
| PHARMACOLOGY | 400 | ||
| 1. Action on the Circulatory System | 400 | ||
| 2. Action on the Striated Muscles | 401 | ||
| 3. Effect on Smooth Muscles | 402 | ||
| 4. Antineoplastic Action | 403 | ||
| 5. Analgesic Action | 403 | ||
| 6. Antipyretic, Anti-inflammatory, Antiallergic and Other Actions | 403 | ||
| 7. Miscelleneous Actions | 404 | ||
| 8. Pharmacokinetics | 404 | ||
| 9. Toxicity | 404 | ||
| CLINICAL STUDIES | 405 | ||
| 1. Hypertension and Coronary Disease | 405 | ||
| 2. Compound Anesthesia | 406 | ||
| 3. Carcinoma | 406 | ||
| 4. Neuralgia | 406 | ||
| 5. Amebic Dysentery | 407 | ||
| ADVERSE EFFECTS | 407 | ||
| REFERENCE | 407 | ||
| BANXIA | 411 | ||
| CHEMICAL COMPOSITION | 411 | ||
| PHARMACOLOGY | 411 | ||
| 1. Antitussive Action | 411 | ||
| 2. Inhibition of Glandular Secretions | 411 | ||
| 3. Antiemetic and Emetic Actions | 411 | ||
| 4. Antineoplastic Action | 412 | ||
| 5. Reducing Effect on Intraocular Pressure | 412 | ||
| 6. Experimental Therapy for Silicosis | 412 | ||
| 7. Action on the Uterus and Pregnancy | 413 | ||
| 8. Miscellaneous Actions | 413 | ||
| 9. Toxicity | 413 | ||
| CLINICAL STUDIES | 414 | ||
| 1. Chronic Bronchitis and Bronchiectasis | 414 | ||
| 2. Emesis of Various Causes | 414 | ||
| 3. Carcinoma of the Cervix | 414 | ||
| 4. Toothache | 415 | ||
| 5. Paranoia | 415 | ||
| 6. Corns | 415 | ||
| ADVERSE EFFECTS | 415 | ||
| REFERENCE | 416 | ||
| BANBIANLIAN | 418 | ||
| CHEMICAL COMPOSITION | 418 | ||
| PHARMACOLOGY | 418 | ||
| 1. Diuretic Action | 418 | ||
| 2. Action on the Nervous System | 418 | ||
| 3. Respiratory Stimulant Action | 419 | ||
| 4. Actions on the Cardiovascular System | 419 | ||
| 5. Choleretic Action | 420 | ||
| 6. Antivenin Action | 420 | ||
| 7. Emetic Action | 420 | ||
| 8. Miscellaneous Actions | 420 | ||
| 9. Toxicity | 421 | ||
| CLINICAL STUDIES | 421 | ||
| 1. Advanced Schistosomiasis with Ascites | 421 | ||
| 2. Acute Nephritis with Edema | 421 | ||
| 3. Snake Bites | 422 | ||
| 4. Skin Diseases | 422 | ||
| 5. Asphyxia Neonatorum and Asphyxia of Other Etiologies | 422 | ||
| 6. Miscellaneous | 422 | ||
| ADVERSE EFFECTS | 422 | ||
| REFERENCE | 423 | ||
| Dilong | 424 | ||
| CHEMICAL COMPOSITION | 424 | ||
| PHARMACOLOGY | 424 | ||
| 1. Antiasthmatic Action | 424 | ||
| 2. Hypotensive Action | 425 | ||
| 3. Actions on the Uterine Smooth Muscles | 425 | ||
| 4. Sedative and Anticonvulsant Actions | 425 | ||
| 5. Antipyretic Action | 426 | ||
| 6. Miscellaneous Actions | 426 | ||
| 7. Toxicity | 426 | ||
| CLINICAL STUDIES | 426 | ||
| 1. Chronic Bronchitis | 426 | ||
| 2. Hypertension | 427 | ||
| 3. High Fever and Convulsion | 427 | ||
| 4. Mumps | 427 | ||
| 5. Miscellaneous | 428 | ||
| ADVERSE EFFECTS | 428 | ||
| REFERENCE | 428 | ||
| DIHUANG | 430 | ||
| CHEMICAL COMPOSITION | 430 | ||
| PHARMACOLOGY | 430 | ||
| 1. Effects on the Adrenocortical Function and Catabolism of Cortisol | 430 | ||
| 2. Antiradiation Action | 431 | ||
| 3. Liver-Protective Action | 431 | ||
| 4. Effect on Blood Glucose | 431 | ||
| 5. Actions on the Cardiovascular System | 432 | ||
| 6. Hemostatic Action | 432 | ||
| 7. Diuretic Action | 433 | ||
| 8. Anti-inflammatory Action | 433 | ||
| 9. Antifungal Action | 433 | ||
| 10. Miscellaneous Actions | 433 | ||
| 11. Toxicity | 433 | ||
| CLINICAL STUDIES | 434 | ||
| 1. Immunologic Diseases | 434 | ||
| 2. Infectious Hepatitis | 434 | ||
| 3. Hypertension | 434 | ||
| 4. Skin Diseases | 434 | ||
| ADVERSE EFFECTS | 434 | ||
| REFERENCE | 434 | ||
| DIYU | 436 | ||
| CHEMICAL COMPOSITION | 436 | ||
| PHARMACOLOGY | 436 | ||
| 1. Hemostatic Action | 436 | ||
| 2. Effects on Burns and Scalds | 436 | ||
| 3. Antiemetic Action | 437 | ||
| 4. Antimicrobial Action | 437 | ||
| 5. Miscellaneous Action | 437 | ||
| CLINICAL STUDIES | 438 | ||
| 1. Upper Gastrointestinal Hemorrhage | 438 | ||
| 2. Functional Uterine Bleeding | 438 | ||
| 3. Purpura of Young Children and Pulmonary Tuberculosis with Hemoptysis | 438 | ||
| 4. Scalds and Burns | 438 | ||
| 5. Bacillary Dysentery | 439 | ||
| 6. Cervix Erosion | 439 | ||
| 7. Skin Diseases | 439 | ||
| REFERENCE | 439 | ||
| DIGUPI | 441 | ||
| CHEMICAL COMPOSITION | 441 | ||
| PHARMACOLOGY | 441 | ||
| 1. Antipyretic Action | 441 | ||
| 2. Hypoglycemic Action | 441 | ||
| 3. Anticholesterolemic Action | 442 | ||
| 4. Actions on the Cardiovascular System | 442 | ||
| 5. Antimicrobial Action | 442 | ||
| 6. Miscellaneous Actions | 442 | ||
| 7. Toxicity | 443 | ||
| CLINICAL STUDIES | 443 | ||
| 1. Cough Due to Pathogenic \"Heat\" in Lung | 443 | ||
| 2. \"Fever Due to Asthenia of Viscera \" and Hemoptysis | 443 | ||
| 3. Hypertension | 443 | ||
| 4. Allergic Diseases of Skin and Mucous Membrane | 444 | ||
| 5. Pulpitis | 444 | ||
| 6. Tinea Manuum | 444 | ||
| 7. Miscellaneous | 444 | ||
| REFERENCE | 444 | ||
| DIJINCAO | 446 | ||
| CHEMICAL COMPOSITION | 446 | ||
| PHARMACOLOGY | 446 | ||
| 1.Antimicrobial Action | 446 | ||
| 2. Detoxicant Action | 447 | ||
| 3. Hemostatic Action | 447 | ||
| 4. Toxicity | 447 | ||
| CLINICAL STUDIES | 447 | ||
| 1. Bacillary Dysentery, Enteritis and Dyspepsia | 447 | ||
| 2. Hemorrhagic Diseases | 448 | ||
| 3. Miscellaneous | 448 | ||
| REFERENCE | 448 | ||
| BAIBU | 451 | ||
| CHEMICAL COMPOSITION | 451 | ||
| PHARMACOLOGY | 451 | ||
| 1. Antitussive and Expectorant Action | 451 | ||
| 2. Action on the Bronchial Smooth Muscles | 451 | ||
| 3. Insecticidal Action | 451 | ||
| 4. Antimicrobial Action | 452 | ||
| CLINICAL STUDIES | 452 | ||
| 1. Pulmonary Tuberculosis | 452 | ||
| 2. Chronic Bronchitis | 452 | ||
| 3. Oxyuriasis | 453 | ||
| 4. Vaginal Trichomoniasis | 453 | ||
| 5. Ancylostomiasis | 453 | ||
| 6. As Pesticide | 453 | ||
| ADVERSE EFFECTS | 454 | ||
| REFERENCE | 454 | ||
| DANGGUI | 456 | ||
| CHEMICAL COMPOSITION | 456 | ||
| PHARMACOLOGY | 456 | ||
| 1. Actions on the Uterus | 456 | ||
| 2. Actions on the Cardiovascular System | 457 | ||
| 3. Effect on the Immunologic Function | 460 | ||
| 4. Anti-inflammatory and Analgesic Actions | 461 | ||
| 5. Anti-Vitamin E Deficiency, Antianemic Actions and Effect on Metabolism | 461 | ||
| 6. Antibacterial Action | 462 | ||
| 7. Miscellaneous Actions | 462 | ||
| 8. Toxicity | 462 | ||
| CLINICAL STUDIES | 463 | ||
| 1. Gynecological Diseases | 463 | ||
| 2. Thromboangiitis Obliterans, Neuralgia, Arthralgia and Myalgia | 463 | ||
| 3. Chronic Nephritis | 464 | ||
| 4. Cerebral Arteriosclerosis | 464 | ||
| 5. Constrictive Aortitis | 464 | ||
| 6. Respiratory Diseases | 465 | ||
| 7. Skin Diseases | 465 | ||
| 8. Bacillary Dysentery | 465 | ||
| 9. Hepatitis | 465 | ||
| 10. Poliomyelitis | 465 | ||
| 11. Anemia | 466 | ||
| 12. Miscellaneous | 466 | ||
| ADVERSE EFFECTS | 466 | ||
| REFERENCE | 466 | ||
| DANGYAO | 471 | ||
| CHEMICAL COMPOSITION | 471 | ||
| PHARMACOLOGY | 471 | ||
| 1. Liver-Protective Action | 471 | ||
| 2. Actions on the Gastrointestinal Tract | 472 | ||
| 3. Actions on the Skin | 472 | ||
| 4. Miscellaneous Actions | 472 | ||
| 5. Toxicity | 473 | ||
| CLINICAL STUDIES | 473 | ||
| 1. Viral Hepatitis | 473 | ||
| 2. Alopecia | 473 | ||
| 3. Miscellaneous Actions | 473 | ||
| ADVERSE EFFECTS | 473 | ||
| REFERENCE | 474 | ||
| ROUGUI | 475 | ||
| CHEMICAL COMPOSITION | 475 | ||
| PHARMACOLOGY | 475 | ||
| 1. Effect on the Gastrointestinal Tract | 475 | ||
| 2. Actions on the Heart and Blood Vessels | 475 | ||
| 3. Incremental Effect on Leukocytes and Radiation Protective Action | 476 | ||
| 4. Antibacterial Action | 476 | ||
| 5. Schistosomicidal Action | 477 | ||
| 6. Toxicity | 477 | ||
| CLINICAL STUDIES | 477 | ||
| 1. \"Cold\" of the Gastrointestinal Tract, Abdominal Pain, and Diarrhea | 477 | ||
| 2. Gastrointestinal Disturbances | 477 | ||
| 3. Bronchial Asthma | 477 | ||
| 4. Asthenia of Blood and Vital Energy | 478 | ||
| ADVERSE EFFECTS | 478 | ||
| REFERENCE | 478 | ||
| YANHUSUO | 479 | ||
| CHEMICAL COMPOSITION | 479 | ||
| PHARMACOLOGY | 479 | ||
| 1. Effects on the Central Nervous System | 479 | ||
| 2. Muscle Relaxant Action | 482 | ||
| 3. Actions on the Cardiovascular System | 482 | ||
| 4. Actions on the Digestive System | 482 | ||
| 5. Effect on the Pituitary-Adrenocortical Function | 483 | ||
| 6. Pharmacokinetics | 483 | ||
| 7. Toxicity | 484 | ||
| CLINICAL STUDIES | 484 | ||
| 1. Analgesia | 484 | ||
| 2. Hypnosis | 485 | ||
| 3. Local Anesthesia | 485 | ||
| 4. Early Hypertension | 485 | ||
| 5. Coronary Disease | 485 | ||
| 6. Gastric Ulcer | 485 | ||
| ADVERSE EFFECTS | 486 | ||
| REFERENCE | 486 | ||
| YANGJIAOYAO | 488 | ||
| CHEMICAL COMPOSITION | 488 | ||
| PHARMACOLOGY | 488 | ||
| 1. Actions on the Heart | 488 | ||
| 2. Excitatory Action on the Uterus | 489 | ||
| 3. Sedative Action | 489 | ||
| 4. Diuretic Action | 489 | ||
| 5. Pharmacokinetics | 490 | ||
| 6. Toxicity | 490 | ||
| CLINICAL STUDIES | 490 | ||
| ADVERSE EFFECTS | 491 | ||
| REFERENCE | 491 | ||
| FANGFENG | 492 | ||
| CHEMICAL COMPOSITION | 492 | ||
| PHARMACOLOGY | 492 | ||
| 1. Antipyretic Action | 492 | ||
| 2. Anti-inflammatory and Analgesic Actions | 492 | ||
| 3. Anticonvulsant Action | 492 | ||
| 4. Antimicrobial Action | 493 | ||
| CLINICAL STUDIES | 493 | ||
| 1. Common Cold | 493 | ||
| 2. Rosacea | 493 | ||
| 3. Elimination of Arsenic | 493 | ||
| REFERENCE | 493 | ||
| HONGHUA (APPENDIX:HONGHUAZIYOU) | 495 | ||
| CHEMICAL COMPOSITION | 495 | ||
| PHARMACOLOGY | 495 | ||
| 1. Actions on the Heart and Blood Vessels | 495 | ||
| 2. Effect on Blood Coagulation | 496 | ||
| 3. Effect on Tolerance to Hypoxia | 497 | ||
| 4. Actions on the Uterus | 497 | ||
| 5. Miscellaneous Actions | 497 | ||
| 6. Toxicity | 498 | ||
| CLINICAL STUDIES | 498 | ||
| 1. Coronary Disease | 498 | ||
| 2. Thrombotic Diseases | 498 | ||
| 3. Menstrual Disturbances | 498 | ||
| 4. Wounds and Decubitus Ulcer | 499 | ||
| 5. Miscellaneous | 499 | ||
| ADVERSE EFFECTS | 499 | ||
| APPENDIX: |
499 | ||
| REFERENCE | 500 | ||
| HONGCITENG | 502 | ||
| CHEMICAL COMPOSITION | 502 | ||
| PHARMACOLOGY | 502 | ||
| 1. Hemostatic Action | 502 | ||
| 2. Antibacterial Action | 503 | ||
| 3. Toxicity | 503 | ||
| CLINICAL STUDIES | 503 | ||
| 1. Bleeding from Traumatic Wounds | 503 | ||
| 2. Internal or Deep Tissue Bleeding Due to Operation or External Trauma | 503 | ||
| REFERENCE | 503 | ||
| MAIDONG | 504 | ||
| CHEMICAL COMPOSITION | 504 | ||
| PHARMACOLOGY | 504 | ||
| 1. Enhancement of Hypoxia Tolerance | 504 | ||
| 2. Hyperglycemic Action | 504 | ||
| 3. Antibacterial Action | 504 | ||
| CLINICAL STUDIES | 505 | ||
| 1. Coronary Disease | 505 | ||
| 2. Cough of the \"Dry-Heat\" Type | 505 | ||
| 3. Late-Stage of Febrile Diseases with Loss of Fluid, Constipation, \"Asthenic Fever\", and Thirst | 505 | ||
| REFERENCE | 505 | ||
| MAIYA (APPENDIX:GUYA, DAMAIGAN AND DAMAIGEN) | 506 | ||
| CHEMICAL COMPOSITION | 506 | ||
| PHARMACOLOGY | 506 | ||
| 1. Digestive Action | 506 | ||
| 2. Hypoglycemic Action | 507 | ||
| 3. Miscellaneous Actions | 507 | ||
| 4. Toxicity | 507 | ||
| CLINICAL STUDIES | 507 | ||
| 1. Dyspepsia | 507 | ||
| 2. Anorexia | 508 | ||
| 3. Malnutrition | 508 | ||
| 4. Restoration of Lactation | 508 | ||
| APPENDIX 1: |
508 | ||
| APPENDIX 2: |
508 | ||
| PHARMACOLOGY | 509 | ||
| 1. Antineoplastic Action | 509 | ||
| 2. Ascaridal Action | 509 | ||
| REFERENCES | 509 | ||
| YUANZHI | 510 | ||
| CHEMICAL COMPOSITION | 510 | ||
| PHARMACOLOGY | 510 | ||
| 1. Expectorant Action | 510 | ||
| 2. Sedative and Anticonvulsant Action | 510 | ||
| 3. Uterine Contraction | 511 | ||
| 4. Hypotensive Action | 511 | ||
| 5. Hemolytic Action | 511 | ||
| 6. Bacteriostatic Action | 511 | ||
| 7. Toxicity | 511 | ||
| CLINICAL STUDIES | 512 | ||
| 1. Neurasthenia, Fear, Amnesia, Insomnia, and Frequent Dreaming | 512 | ||
| 2. Chronic Bronchitis | 512 | ||
| REFERENCE | 512 | ||
| GANGLIUPI | 513 | ||
| CHEMICAL COMPOSITION | 513 | ||
| PHARMACOLOGY | 513 | ||
| 1. Cardiotonic Action | 513 | ||
| 2. Central Action | 514 | ||
| 3. Cholinergic Action | 514 | ||
| 4. Anti-inflammatory Action | 514 | ||
| 5. Miscellaneous Actions | 515 | ||
| 6. Toxicity | 515 | ||
| CLINICAL STUDIES | 515 | ||
| 1. Congestive Heart Failure | 515 | ||
| 2. Rheumatic Arthritis | 515 | ||
| ADVERSE EFFECTS | 516 | ||
| REFERENCE | 516 | ||
| DUZHONG | 517 | ||
| CHEMICAL COMPOSITION | 517 | ||
| PHARMACOLOGY | 517 | ||
| 1. Actions on the Cardiovascular System | 517 | ||
| 2. Sedative and Analgesic Actions | 519 | ||
| 3. Anti-inflammatory Action | 519 | ||
| 4. Actions on the Uterus | 520 | ||
| 5. Effect on the Phagocytic Function of Reticuloendothelial system | 520 | ||
| 6. Diuretic Action | 520 | ||
| 7. Miscellaneous Actions | 520 | ||
| 8.Toxicity | 521 | ||
| CLINICAL STUDIES | 521 | ||
| 1. Hypertension | 521 | ||
| 2. Rheumatic Arthritis and Lumbago | 522 | ||
| REFERENCE | 522 | ||
| YUANHUA | 524 | ||
| CHEMICAL COMPOSITION | 524 | ||
| PHARMACOLOGY | 524 | ||
| 1. Actions on the Digestive System | 524 | ||
| 2. Diuretic Action | 524 | ||
| 3. Antitussive and Expectorant Actions | 525 | ||
| 4. Abortifacient Action | 525 | ||
| 5. Antibacterial Action | 526 | ||
| 6. Miscellaneous Actions | 526 | ||
| 7. Toxicity | 526 | ||
| CLINICAL STUDIES | 527 | ||
| 1. Acute and Chronic Hepatitis | 527 | ||
| 2. Ascites | 527 | ||
| 3. Chronic Bronchitis | 527 | ||
| 4. Induction of Labor | 527 | ||
| 5. Miscellaneous Actions | 528 | ||
| ADVERSE EFFECTS | 528 | ||
| REFERENCE | 528 | ||
| YUNXIANGCAO | 531 | ||
| CHEMICAL COMPOSITION | 531 | ||
| PHARMACOLOGY | 531 | ||
| 1. Antiasthmatic Action | 531 | ||
| 2. Action on Other Smooth Muscles | 532 | ||
| 3. Antitussive Action | 532 | ||
| 4. Antibacterial Action | 532 | ||
| 5. Central Action | 533 | ||
| 6. Toxicity | 533 | ||
| CLINICAL STUDIES | 533 | ||
| ADVERSE EFFECTS | 533 | ||
| REFERENCE | 533 | ||
| QINCAI | 535 | ||
| CHEMICAL COMPOSITION | 535 | ||
| PHARMACOLOGY | 535 | ||
| 1. Hypotensive Action | 535 | ||
| 2. Central Action | 536 | ||
| 3. Antibacterial Action | 536 | ||
| 4. Miscellaneous Actions | 536 | ||
| 5. Toxicity | 536 | ||
| CLINICAL STUDIES | 536 | ||
| 1. Hypertension | 536 | ||
| 2. Hypercholesterolemia | 537 | ||
| 3. Chyluria | 537 | ||
| REFERENCE | 537 | ||
| CANGZHU | 538 | ||
| CHEMICAL COMPOSITION | 538 | ||
| PHARMACOLOGY | 538 | ||
| 1. As Antiseptic Fumigant | 538 | ||
| 2. Hypoglycemic Action | 538 | ||
| 3. Diuretic Action | 539 | ||
| 4. Miscellaneous Actions | 539 | ||
| 5. Toxicity | 539 | ||
| CLINICAL STUDIES | 540 | ||
| 1. Acute and Chronic Gastritis, Vomiting, Diarrhea, Upper Abdominal Distention, Intestinal Gurgling, and Abdominal Pain | 540 | ||
| 2. Induction of Labor in Case of lntrauterine Fetal Death and in Early Pregnancy | 540 | ||
| 3. Sterilization | 540 | ||
| 4. Prophylaxis of Varicella, Mumps, Scarlet Fever, Common Cold, and Bronchitis | 540 | ||
| 5. Skin Diseases | 540 | ||
| 6. Sinus Tachycardia | 541 | ||
| 7. Weakness of Lower Limbs and Profuse Yellow Leukorrhea | 541 | ||
| 8. Toxic Reaction of Streptomycin | 541 | ||
| 9. Night Blindness | 541 | ||
| 10. Malaria | 541 | ||
| REFERENCE | 542 | ||
| CANG' ERZI (APPENDIX: CANG' ERCAO) | 544 | ||
| CHEMICAL COMPOSITION | 544 | ||
| PHARMACOLOGY | 544 | ||
| 1. Hypoglycemic Action | 544 | ||
| 2. Actions on the Respiratory System | 545 | ||
| 3. Actions on the Cardiovascular System | 545 | ||
| 4. Antimicrobial Action | 545 | ||
| 5. Miscellaneous Actions | 545 | ||
| 6. Toxicity | 545 | ||
| CLINICAL STUDIES | 546 | ||
| 1. Chronic Paranasal Sinusitis | 546 | ||
| 2. Allergic Rhinitis | 547 | ||
| 3. Chronic Rhinitis | 547 | ||
| 4. Chronic Bronchitis | 547 | ||
| 5. Lumbago | 547 | ||
| 6. Malaria | 547 | ||
| 7. Miscellaneous | 547 | ||
| APPENDIX: |
548 | ||
| CLINICAL COMPOSITION | 548 | ||
| PHARMACOLOGY | 548 | ||
| TOXICITY | 549 | ||
| CLINICAL STUDIES | 549 | ||
| 1. Leprosy | 549 | ||
| 2. Acute Bacillary Dysentery | 549 | ||
| 3. Miscellaneous | 549 | ||
| ADVERSE EFFECTS | 549 | ||
| REFERENCE | 550 | ||
| LIANQIAO | 552 | ||
| CHEMICAL COMPOSITION | 552 | ||
| PHARMACOLOGY | 552 | ||
| 1. Antimicrobial Action | 552 | ||
| 2. Anti-inflammatory Action | 552 | ||
| 3. Antipyretic Action | 553 | ||
| 4. Antiemetic Action | 553 | ||
| 5. Diuretic Action | 553 | ||
| 6. Actions on the Cardiovascular System | 554 | ||
| 7. Action Against Liver Damage | 554 | ||
| 8. Toxicity | 554 | ||
| CLINICAL STUDIES | 555 | ||
| 1. Acute Infectious Diseases | 555 | ||
| 2. Lung Abscess | 555 | ||
| 3. Cervical Lymph Node Tuberculosis and Pulmonary Tuberculosis | 555 | ||
| 4. Skin Infections | 555 | ||
| 5. Acute Nephritis | 556 | ||
| 6. Acute Viral Hepatitis | 556 | ||
| 7. Miscellaneous | 556 | ||
| REFERENCE | 556 | ||
| WUZHUYU | 558 | ||
| CHEMICAL COMPOSITION | 558 | ||
| PHARMACOLOGY | 558 | ||
| 1. Actions on the Digestive System | 558 | ||
| 2. Analgesic Action | 558 | ||
| 3. Action on the Circulatory System | 559 | ||
| 4. Action on the Uterus | 559 | ||
| 5. Antibacterial Action | 560 | ||
| 6. Miscellaneous Actions | 560 | ||
| CLINICAL STUDIES | 560 | ||
| 1. Vomiting and Abdominal Pain | 560 | ||
| 2. Chronic Diarrhea Due to \"Cold\" and Asthenia, and \"Morning Diarrhea | 560 | ||
| 3. Uterine Dystonia and Uterine Bleeding | 560 | ||
| 4. Hypertension and Migraine | 560 | ||
| 5. Oral Candidiasis | 561 | ||
| 6. Pustulosis, Eczema, and Neurodermatitis | 561 | ||
| REFERENCE | 561 | ||
| MUJING | 563 | ||
| CHEMICAL COMPOSITION | 563 | ||
| PHARMACOLOGY | 563 | ||
| 1. Expectorant, Antitussive and Antiasthmatic Actions | 563 | ||
| 2. Actions on Smooth Muscles and Blood Pressure | 564 | ||
| 3. Sedative and Hypnotic Actions | 564 | ||
| 4. Effect on the Adrenocortical Function and Reticuleondothelial System | 564 | ||
| 5. Antibacterial Action | 564 | ||
| 6. Toxicity | 565 | ||
| CLINICAL STUDIES | 565 | ||
| 1. Chronic Bronchitis | 565 | ||
| 2. Cough and Dyspnea in Children | 566 | ||
| 3. Miscellaneous | 566 | ||
| REFERENCE | 566 | ||
| MUDANPI | 568 | ||
| CHEMICAL COMPOSITION | 568 | ||
| PHARMACOLOGY | 568 | ||
| 1. Antimicrobial Action | 568 | ||
| 2. Anti-inflammatory Action | 568 | ||
| 3. Hypotensive Action | 569 | ||
| 4. Actions on the Central Nervous System | 569 | ||
| 5. Miscellaneous Actions | 569 | ||
| 6. Pharmacokinetics | 569 | ||
| 7. Toxicity | 570 | ||
| CLINICAL STUDIES | 570 | ||
| 1. Appendicitis | 570 | ||
| 2. Bacillary Dysentery | 570 | ||
| 3. Hypertension | 570 | ||
| 4. Allergic Rhinitis and Others | 570 | ||
| ADVERSE EFFECTS | 571 | ||
| REFERENCE | 571 | ||
| HESHOUWU | 572 | ||
| CHEMICAL COMPOSITION | 572 | ||
| PHARMACOLOGY | 572 | ||
| 1. Actions on the Heart and Blood Vessels | 572 | ||
| 2. Effects on Blood Lipids and Atherosclerosis | 572 | ||
| 3. Effect on the Animals' Resistance to Cold | 573 | ||
| 4. Antibacterial Action | 573 | ||
| 5. Miscellaneous Actions | 573 | ||
| CLINICAL STUDIES | 574 | ||
| 1. Hypercholesterolemia | 574 | ||
| 2. Neurasthenia | 574 | ||
| 3. Schizophrenia | 574 | ||
| 4. Miscellaneous | 574 | ||
| ADVERSE EFFECTS | 575 | ||
| REFERENCE | 575 | ||
| FOSHOU | 577 | ||
| CHEMICAL COMPOSITION | 577 | ||
| PHARMACOLOGY | 577 | ||
| 1. Antiasthmatic and Expectorant Actions | 577 | ||
| 2. Action on the Gastrointestinal Smooth Muscles | 578 | ||
| 3. Central Inhibitory Action | 578 | ||
| 4. Actions on the Cardiovascular System | 578 | ||
| 5. Toxicity | 578 | ||
| CLINICAL STUDIES | 578 | ||
| 1. Dyspepsia | 578 | ||
| 2. Chronic Bronchitis and Pulmonary Emphysema | 579 | ||
| 3. Hepatobiliary Diseases | 579 | ||
| APPENDIX: |
579 | ||
| REFERENCE | 579 | ||
| XINYI | 581 | ||
| CHEMICAL COMPOSITION | 581 | ||
| PHARMACOLOGY | 581 | ||
| 1. Local Astringent, Stimulant and Anesthetic Actions | 581 | ||
| 2. Hypotensive Action | 582 | ||
| 3. Actions on Striated Muscles | 582 | ||
| 4. Actions on the Uterus and Intestinal Smooth Muscles | 583 | ||
| 5. Antimicrobial Action | 583 | ||
| 6. Toxicity | 584 | ||
| CLINICAL STUDIES | 584 | ||
| 1. Rhinitis and Paranasal Sinusitis | 584 | ||
| 2. Miscellaneous | 585 | ||
| ADVERSE EFFECTS | 585 | ||
| REFERENCE | 585 | ||
| BUGUZHI | 588 | ||
| CHEMICAL COMPOSITION | 588 | ||
| PHARMACOLOGY | 588 | ||
| 1. Actions on the Cardiovascular System | 588 | ||
| 2. Hemostatic Action | 589 | ||
| 3. Photosensitive Action | 589 | ||
| 4. Anti-implantation and Estrogenic Actions | 589 | ||
| 5. Actions on Smooth Muscles | 589 | ||
| 6. Antibacterial Action | 589 | ||
| 7. Miscellaneous Actions | 590 | ||
| 8. Toxicity | 590 | ||
| CLINICAL STUDIES | 590 | ||
| 1. Gynecological Bleeding and Other Bleeding Symptoms | 590 | ||
| 2. Psoriasis | 590 | ||
| 3. Vitiligo | 591 | ||
| 4. Corns and Alopecia | 591 | ||
| 5. Miscellaneous | 591 | ||
| REFERENCE | 591 | ||
| LINGZHI | 593 | ||
| CHEMICAL COMPOSITION | 593 | ||
| PHARMACOLOGY | 593 | ||
| 1. Actions on the Central Nervous System | 593 | ||
| 2. Effect on the Autonomic Nervous System | 594 | ||
| 3. Actions on the Respiratory System | 594 | ||
| 4. Actions on the Cardiovascular System | 594 | ||
| 5. Liver-Protective and Detoxicant Actions | 596 | ||
| 6. Actions on the Intestinal and Uterine Smooth Muscles | 596 | ||
| 7. Effects on Endocrine Functions and Metabolism | 597 | ||
| 8. Regulation of the Immunologic Function and Inhibition of Allergic Reaction | 597 | ||
| 9. Anti-irradiation Action | 598 | ||
| 10. Effect on High Serum Aldolase in Experimental Myotonic Mice | 598 | ||
| 11. Miscellaneous Actions | 598 | ||
| 12. Toxicity | 599 | ||
| CLINICAL STUDIES | 599 | ||
| 1. Coronary Disease and Hyperlipidemia | 599 | ||
| 2. Chronic Bronchitis | 599 | ||
| 3. Acute Altitude Sickness | 600 | ||
| 4. Hepatitis | 600 | ||
| 5. Keshan Disease | 600 | ||
| 6. Miscellaneous | 600 | ||
| REFERENCE | 601 | ||
| EJIAO (APPENDIX:XIN' EJIAO) | 604 | ||
| CHEMICAL COMPOSITON | 604 | ||
| PHARMACOLOGY | 604 | ||
| 1. Actions on the Hematopoietic System | 604 | ||
| 2. Antishock Action | 604 | ||
| 3. Effect on Progressive Muscular Dystrophy | 605 | ||
| 4. Effect on Calcium Metabolism | 605 | ||
| 5. Miscellaneous Actions | 605 | ||
| CLINICAL STUDIES | 606 | ||
| 1. Diseases of the Hematopoietic System | 606 | ||
| 2. Threatened Abortion | 606 | ||
| 3. Hemorrhage | 606 | ||
| 4. Miscellaneous | 606 | ||
| APPENDIX: |
607 | ||
| REFERENCE | 607 | ||
| CHENPI | 609 | ||
| CHEMICAL COMPOSITION | 609 | ||
| PHARMACOLOGY | 609 | ||
| 1. Actions on the Gastrointestinal Smooth Muscles | 609 | ||
| 2. Expectorant and Antiasthmatic Actions | 610 | ||
| 3. Antiallergic Action | 610 | ||
| 4. Antigastric Ulcer Action | 611 | ||
| 5. Choleretic Action | 611 | ||
| 6. Actions on the Cardiovascular System | 611 | ||
| 7. Action on the Uterus | 613 | ||
| 8. Effect on the Kidneys | 613 | ||
| 9. Miscellaneous Actions | 613 | ||
| 10. Pharmacokinetics | 613 | ||
| 11. Toxicity | 614 | ||
| CLINICAL STUDIES | 614 | ||
| 1. Dyspepsia | 614 | ||
| 2. Cough and Expectoration | 614 | ||
| 3. Miscellaneous | 615 | ||
| REFERENCE | 615 | ||
| FUZI AND CHUANWU | 617 | ||
| CHEMICAL COMPOSITION | 617 | ||
| PHARMACOLOGY | 617 | ||
| 1. Cardiotonic Action | 617 | ||
| 2. Actions on the Blood Vessels and Blood Pressure | 618 | ||
| 3. Actions on the Autonomic Nervous System | 618 | ||
| 4. Action on the Central Nervous System | 619 | ||
| 5. Anti-inflammatory Action | 619 | ||
| 6. Local Anesthetic Action | 619 | ||
| 7. Antihypothermic Action | 619 | ||
| 8. Toxicity | 620 | ||
| CLINICAL STUDIES | 620 | ||
| 1. Heart Failure | 620 | ||
| 2. Thromboangiitis Obliterans | 620 | ||
| 3. Chronic Infantile Diarrhea | 620 | ||
| ADVERSE EFFECTS | 621 | ||
| REFERENCE | 621 | ||
| JI' NEIJIN | 623 | ||
| CHEMICAL COMPOSITION | 623 | ||
| PHARMACOLOGY | 623 | ||
| 1. Effect on Human Gastric Function | 623 | ||
| 2. Acceleration of the Excretion of Radioactive Strontium | 623 | ||
| CLINICAL STUDIES | 624 | ||
| 1. Dyspepsia | 624 | ||
| 2. Enuresis in Children, Pollakiuria, and Nocturia in Adults | 624 | ||
| 3. Asthenia and Seminal Emission | 624 | ||
| REFERENCE | 624 | ||
| JISHITENG | 625 | ||
| CHEMICAL COMPOSITION | 625 | ||
| PHARMACOLOGY | 625 | ||
| 1. Analgesic and Sedative Actions | 625 | ||
| 2. Actions on Smooth Muscles | 625 | ||
| 3. Expectorant Action | 625 | ||
| 4. Antibacterial Action | 626 | ||
| 5. Hypotensive Action | 626 | ||
| 6. Local Anesthetic Action | 626 | ||
| 7. Toxicity | 626 | ||
| CLINICAL STUDIES | 626 | ||
| 1. Analgesia | 626 | ||
| 2. Induction of Labor | 627 | ||
| 3. Respiratory Tract Diseases | 627 | ||
| 4. Skin Diseases | 627 | ||
| ADVERSE EFFECTS | 627 | ||
| REFERENCE | 628 | ||
| QINGPI | 629 | ||
| CHEMICAL COMPOSITION | 629 | ||
| PHARMACOLOGY | 629 | ||
| 1. Expectorant and Antiasthmatic Actions | 629 | ||
| 2. Actions on Intestinal Smooth Muscles | 629 | ||
| 3. Pressor Action | 630 | ||
| CLINICAL STUDIES | 630 | ||
| 1. Bronchial Asthma | 630 | ||
| 2. Dyspepsia and Postoperative Abdominal Distention | 630 | ||
| 3. Pain Due to Liver and Gallbladder Diseases | 631 | ||
| REFERENCE | 631 | ||
| QINGHAO | 632 | ||
| CHEMICAL COMPOSITION | 632 | ||
| PHARMACOLOGY | 632 | ||
| 1. Antimalarial Action | 632 | ||
| 2. Antischistosomal Action | 634 | ||
| 3. Actions on the Cardiovascular System | 634 | ||
| 4. Antipyretic and Analgesic Actions | 634 | ||
| 5. Miscellaneous Actions | 635 | ||
| 6. Pharmacokinetics | 635 | ||
| 7. Toxicity | 635 | ||
| CLINICAL STUDIES | 636 | ||
| 1. Malaria | 636 | ||
| 2. Lupus Erythematosus | 636 | ||
| 3. Clonorchiasis | 637 | ||
| 4. Chronic Bronchitis and Bronchial Asthma | 637 | ||
| 5. Pruritus, Urticaria, and Seborrheic Dermatitis | 637 | ||
| 6. Mosquito Repellent | 637 | ||
| 7. Heat Stroke | 637 | ||
| ADVERSE EFFECTS | 638 | ||
| REFERENCE | 638 | ||
| QINGDAI | 640 | ||
| CHEMICAL COMPOSITION | 640 | ||
| PHARMACOLOGY | 640 | ||
| 1. Antineoplastic Action | 640 | ||
| 2. Effect on Leukocytes | 641 | ||
| 3. Liver-Protective Action | 642 | ||
| 4. Antibacterial Action | 642 | ||
| 5. Miscellaneous Actions | 642 | ||
| 6. Pharmacokinetics | 642 | ||
| 7. Toxicity | 643 | ||
| CLINICAL STUDIES | 643 | ||
| 1. Chronic Granulocytic Leukemia and Other Hematological Diseases | 643 | ||
| 2. Mumps, Viral Hepatitis and Eczema | 644 | ||
| ADVERSE EFFECTS | 644 | ||
| REFERENCE | 645 | ||
| QINGMUXIANG | 647 | ||
| CHEMICAL COMPOSITION | 647 | ||
| PHARMACOLOGY | 647 | ||
| 1. Hypotensive Action | 647 | ||
| 2. Action on Smooth Muscles | 648 | ||
| 3. Antineoplastic Action | 648 | ||
| 4. Antibacterial Action and Incremental Effect on the Immunologic Function | 648 | ||
| 5. Miscellaneous Actions | 648 | ||
| 6. Toxicity | 649 | ||
| CLINICAL STUDIES | 649 | ||
| 1. Hypertension | 649 | ||
| 2. Stomachache | 649 | ||
| 3. Infectious Diseases | 649 | ||
| 4. As Adjuvant to Chemotherapy and Radiotherapy of Carcinoma | 650 | ||
| ADVERSE EFFECTS | 650 | ||
| REFERENCE | 650 | ||
| QINGFENGTENG | 652 | ||
| CHEMICAL COMPOSITION | 652 | ||
| PHARMACOLOGY | 652 | ||
| 1. Analgesic Action | 652 | ||
| 2. Sedative Action | 652 | ||
| 3. Antitussive Action | 653 | ||
| 4. Anti-inflammatory and Antiallergic Actions | 653 | ||
| 5. Hypotensive Action | 653 | ||
| 6. Effect on the Gastrointestinal Tract | 654 | ||
| 7. Histamine-Releasing Action | 654 | ||
| 8. Miscellaneous Action | 655 | ||
| 9. Toxicity | 655 | ||
| CLINICAL STUDIES | 655 | ||
| Rheumatic and Rheumatoid Arthritis | 655 | ||
| REFERENCE | 656 | ||
| BANLAN' GEN | 658 | ||
| CHEMICAL COMPOSITION | 658 | ||
| PHARMACOLOGY | 658 | ||
| 1. Antiviral Action | 658 | ||
| 2. Antibacterial Action | 658 | ||
| CLINICAL STUDIES | 659 | ||
| 1. Encephalitis B | 659 | ||
| 2. Chickenpox | 659 | ||
| 3. Hepatitis | 659 | ||
| 4. Mumps | 659 | ||
| 5. Influenza | 660 | ||
| 6. Infectious Mononucleosis | 660 | ||
| 7. Viral Skin Diseases | 660 | ||
| 8. Epidemic Cerebrospinal Meningitis | 660 | ||
| 9. Diphtheria | 660 | ||
| 10. Miscellaneous | 661 | ||
| ADVERSE EFFECTS | 661 | ||
| REFERENCE | 661 | ||
| SONGLUO | 663 | ||
| CHEMICAL COMPOSITION | 663 | ||
| PHARMACOLOGY | 663 | ||
| 1. Antibacterial action | 663 | ||
| 2. Detoxicant Action | 665 | ||
| 3. Actions on Other Pathogenic Organisms | 665 | ||
| 4. Miscellaneous Actions | 665 | ||
| 5. Toxicity | 666 | ||
| CLINICAL STUDIES | 666 | ||
| 1. Pulmonary Tuberculosis | 666 | ||
| 2. Surgical Infections | 667 | ||
| 3. Chronic Bronchitis | 667 | ||
| ADVERSE EFFECTS | 667 | ||
| REFERENCE | 667 | ||
| CIWUJIA | 670 | ||
| CHEMICAL COMPOSITION | 670 | ||
| PHARMACOLOGY | 670 | ||
| 1. Actions on the Central Nervous System | 670 | ||
| 2. Regulation of Body Reaction to Non-specific Stimuli | 671 | ||
| 3. Effect on Immunity | 673 | ||
| 4. Antineoplastic Action | 674 | ||
| 5. Anti-inflammatory Action | 674 | ||
| 6. Actions on the Cardiovascular System | 674 | ||
| 7. Effect on Metabolism and Tissue Regeneration | 675 | ||
| 8. Actions on Chronic Bronchitis (4,39,40) | 675 | ||
| 9. Toxicity | 676 | ||
| CLINICAL STUDIES | 676 | ||
| 1. Neurosis | 676 | ||
| 2. Leukopenia | 677 | ||
| 3. Coronary Disease | 677 | ||
| 4. Acute Obstructive Cerebral Thrombosis | 677 | ||
| 5. Chronic Bronchitis in Elderly Patients | 677 | ||
| 6. Rheumatic Arthritis | 678 | ||
| 7. Acute Altitude Sickness | 678 | ||
| 8. Miscellaneous | 678 | ||
| REFERENCE | 678 | ||
| KUSHEN | 681 | ||
| CHEMICAL COMPOSITION | 681 | ||
| PHARMACOLOGY | 681 | ||
| 1. Actions on the Circulatory System | 681 | ||
| 2. Antiasthmatic and Expectorant Actions | 682 | ||
| 3. Actions on Smooth Muscles | 683 | ||
| 4. Prophylaxis of Leukopenia | 683 | ||
| 5. Antimicrobial Actions | 683 | ||
| 6. Diuretic Action | 683 | ||
| 7. Antineoplastic Action | 684 | ||
| 8. Pharmacokinetics | 684 | ||
| 9. Toxicity | 684 | ||
| CLINICAL STUDIES | 685 | ||
| 1. Arrhythmia Such as Ventricular Premature Beats | 685 | ||
| 2. Acute Bacillary Dysentery | 685 | ||
| 3. Trichomoniasis | 685 | ||
| 4. Leukopenia | 685 | ||
| 5. Skin Diseases | 685 | ||
| 6. Miscellaneous | 686 | ||
| ADVERSE EFFECTS | 686 | ||
| REFERENCE | 686 | ||
| INDEX OF SCIENTIFIC NAMES | 689 | ||
| INDEX OF PHARMACOLOGICAL ACTIONS | 699 | ||
| INDEX OF CHINESE DRUGS | 721 |